Literature DB >> 29454848

Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection.

M L Davis1, H G Sparrow2, J O Ikwuagwu1, W L Musick1, K W Garey3, K K Perez4.   

Abstract

OBJECTIVES: Clostridium difficile infection (CDI) is the most common cause of healthcare-associated infections in the United States. Despite well-established risk factors, little research has focused on use of these variables to identify a patient population at high risk for CDI to target with primary prevention strategies. A predictive index for healthcare-associated CDI could improve clinical care and guide research for primary prevention trials. Our objective was to develop a predictive index to identify patients at high risk for healthcare-associated CDI.
METHODS: We performed a secondary database analysis in a five-hospital health system in Houston, Texas. Our cohort consisted of 97 130 hospitalized patients admitted for more than 48 hours between October 2014 and September 2016. The derivation cohort consisted of the initial 80% of admissions (75 545 patients), with the remainder being used in the validation cohort.
RESULTS: CDI rates in the derivation and validation cohorts were 1.55% and 1.43%, respectively. Thirty-day predictors of CDI were increased number of high-risk antibiotics, Charlson comorbidity index score, age and receipt of a proton pump inhibitor. These variables were incorporated into a simple risk index with a score range of 0 to 10. The final model demonstrated good discrimination and calibration with the observed CDI incidence ranging from 0.1% to 20.4%.
CONCLUSIONS: We developed a predictive index for 30-day risk of healthcare-associated CDI using readily available and clinically useful variables. This simple predictive risk index may be used to improve clinical decision making and resource allocation for CDI stewardship initiatives, and guide research design.
Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anaerobic infection; Antibiotics; Infection control; Secondary database analysis; Surveillance

Mesh:

Year:  2018        PMID: 29454848     DOI: 10.1016/j.cmi.2018.02.013

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Molecular epidemiology of Clostridioides difficile in domestic dogs and zoo animals.

Authors:  M Jahangir Alam; Jacob McPherson; Julie Miranda; Allyson Thrall; Van Ngo; Rebecca Kessinger; Khurshida Begum; Maud Marin; Kevin W Garey
Journal:  Anaerobe       Date:  2019-06-15       Impact factor: 3.331

2.  Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection.

Authors:  Kevin W Garey
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

3.  Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings.

Authors:  Jinhee Jo; Anne J Gonzales-Luna; Chris K Lancaster; Jacob K McPherson; Khurshida Begum; M Jahangir Alam; Kevin W Garey
Journal:  Anaerobe       Date:  2022-02-25       Impact factor: 2.837

4.  Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge.

Authors:  Kelly R Reveles; Kierra M Dotson; Anne Gonzales-Luna; Dhara Surati; Bradley T Endres; M Jahangir Alam; Kevin W Garey
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

5.  Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis.

Authors:  Alexandre R Marra; Eli N Perencevich; Richard E Nelson; Matthew Samore; Karim Khader; Hsiu-Yin Chiang; Margaret L Chorazy; Loreen A Herwaldt; Daniel J Diekema; Michelle F Kuxhausen; Amy Blevins; Melissa A Ward; Jennifer S McDanel; Rajeshwari Nair; Erin Balkenende; Marin L Schweizer
Journal:  JAMA Netw Open       Date:  2020-01-03

6.  A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects.

Authors:  Kevin W Garey; Khurshida Begum; Chris Lancaster; Anne Gonzales-Luna; Dinh Bui; Julie Mercier; Corinne Seng Yue; Murray P Ducharme; Ming Hu; Bradley Vince; Michael H Silverman; M Jahangir Alam; Martin Kankam
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.